Antibody binding specifically to CD40 and use thereof
The present invention relates to an anti-CD40 antibody binding specifically to CD40 and use thereof and, particularly, provides an anti-CD40 antibody or an antigen-binding fragment thereof, and a pharmaceutical composition comprising the same antibody or fragment as an effective ingredient for prevention and/or treatment of cancer, cancer metastasis, infection, and/or immune deficiency diseases.
1. An anti-CD40 antibody or an antigen-binding fragment thereof, comprising the following complementarity determining region (CDRs):
CDR-H1 comprising the amino acid sequence of SEQ ID NO: 17 or SEQ ID NO: 33,
CDR-H2 comprising the amino acid sequence of SEQ ID NO: 18 or SEQ ID NO: 34,
CDR-H3 comprising the amino acid sequence of SEQ ID NO: 19,
CDR-L1 comprising the amino acid sequence of SEQ ID NO: 20 or SEQ ID NO: 35,
CDR-L2 comprising the amino acid sequence of SEQ ID NO: 21 or SEQ ID NO: 36, and
CDR-L3 comprising the amino acid sequence of SEQ ID NO: 22.
2. The anti-CD40 antibody or the antigen-binding fragment thereof according to claim 1 , comprising:
a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 1, 23, 24, 25, 26, 27, or 28; and
a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 3, 29, or 30.
3. The anti-CD40 antibody or the antigen-binding fragment thereof according to claim 1 , wherein the anti-CD40 antibody is an animal antibody, a chimeric antibody, or a humanized antibody.
4. The anti-CD40 antibody or the antigen-binding fragment thereof according to claim 1 , wherein the antigen-binding fragment is scFv, (scFv)2, Fab, Fab′, or F(ab′)2 of the anti-CD40 antibody.
5. The anti-CD40 antibody or the antigen-binding fragment thereof according to claim 1 , having an agonist activity for CD40.
6. A pharmaceutical composition comprising the anti-CD40 antibody or the antigen-binding fragment thereof according to claim 1 .
7. A nucleic acid encoding the anti-CD40 antibody or the antigen-binding fragment thereof according to claim 1 .
8. The nucleic acid according to claim 7 , encoding either or both of:
an amino acid sequence comprising SEQ ID NO: 17 or SEQ ID NO: 33, and SEQ ID NO: 18 or SEQ ID NO: 34, and SEQ ID NO: 19; and
an amino acid sequence comprising SEQ ID NO: 20 or SEQ ID NO: 35, and SEQ ID NO: 21 or SEQ ID NO: 36, and SEQ ID NO: 22.
9. The nucleic acid of claim 7 , encoding either or both of:
the amino acid sequence of SEQ ID NO: 1, 23, 24, 25, 26, 27, or 28; and
the amino acid sequence of SEQ ID NO: 3, 29, or 30.
10. A recombinant vector comprising the nucleic acid of claim 8 .
11. A recombinant cell comprising the recombinant vector of claim 10 .
12. An anti-CD40 antibody or an antigen-binding fragment thereof, which comprise CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of an anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381.
13. The anti-CD40 antibody or an antigen-binding fragment thereof according to claim 12 , which comprise a heavy chain variable region and a light chain variable region of an anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381.
14. The anti-CD40 antibody or an antigen-binding fragment thereof according to claim 12 , wherein the anti-CD40 antibody is produced by the hybridoma of accession number KCLRF-BP-00381.
15. A hybridoma, deposited with accession number KCLRF-BP-00381, for producing an anti-CD40 antibody.
16. A method of treating a disease, the method comprising administering the anti-CD40 antibody or the antigen-binding fragment thereof according to claim 1 to a subject in need of treating the disease, wherein the disease is selected from the group consisting of cancer and cancer metastasis.
17. The method of claim 16 , wherein the anti-CD40 antibody or the antigen-binding fragment thereof comprises:
a heavy-chain variable region comprising the amino acid sequence of SEQ ID NO: 1, 23, 24, 25, 26, 27, or 28; and
a light-chain variable region comprising the amino acid sequence of SEQ ID NO: 3, 29, or 30.
18. A method of treating a disease, the method comprising administering an anti-CD40 antibody or an antigen-binding fragment thereof to a subject in need of treating the disease, wherein the disease is selected from the group consisting of cancer and cancer metastasis, wherein the anti-CD40 antibody is selected from the group consisting of:
an anti-CD40 antibody produced by hybridoma of accession number KCLRF-BP-00381, or an antigen-binding fragment thereof;
an anti-CD40 antibody comprising CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of the anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381, or an antigen-binding fragment thereof;
and an anti-CD40 antibody comprising the heavy-chain and light-chain variable regions of the anti-CD40 antibody produced by the hybridoma of accession number KCLRF-BP-00381, or an antigen-binding fragment thereof.